RO5024048 + danoprevir

**RO5024048 + danoprevir** is an investigational combination therapy studied for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotype 1. RO5024048 (also known as RG7128) is a nucleoside polymerase inhibitor (a prodrug of a cytidine analogue) that targets the HCV NS5B RNA-dependent RNA polymerase, inhibiting viral replication. Danoprevir (ITMN-191) is a small molecule inhibitor of the HCV NS3/4A protease, a key enzyme for viral replication and polyprotein processing. The combination has been studied with and without background therapies (such as ritonavir boosting, ribavirin, and peginterferon alpha-2a), particularly in interferon-naïve or null responder patients with chronic HCV. Both agents act through distinct, complementary mechanisms, aiming to improve sustained virological response rates and overcome resistance seen with monotherapies or traditional interferon/ribavirin regimens[1][3][5].

Other names

RO5024048 + danoprevirRG7128 + danoprevirITMN-191 + RO5024048